MENU

Leading brokers name 3 ASX shares to buy today

The broker reports have been coming in thick and fast after last week’s exceptionally busy period of results releases.

Three shares that have found favour with brokers are listed below. Here’s why they have been given buy ratings:

Mayne Pharma Group Ltd (ASX: MYX)

According to a note out of Credit Suisse, it has retained its outperform rating and lifted the price target on the pharmaceutical company’s shares to $1.20. The broker appears to have been pleasantly surprised by Mayne Pharma’s better than expected full year results last week. And although it has concerns about increasing competition for its key Dofetilide product, it expects this to be offset by new product launches. While it isn’t the bargain buy it was six months ago, I would have to agree with Credit Suisse that Mayne Pharma’s shares are in the buy zone still.

Medibank Private Ltd (ASX: MPL)

A note out of Deutsche Bank reveals that its analysts have retained their buy rating and $3.40 price target on the private health insurance company’s shares despite last week’s disappointing full year results release. According to the note, the broker saw enough in its results to believe that Medibank Private’s core business in back on track. I’m not as bullish on Medibank Private right now and would suggest investors wait for a better entry point at a much lower price.

Westpac Banking Corp (ASX: WBC)

Analysts at Goldman Sachs have retained their buy rating but lowered their price target on this banking giant’s shares to $34.43. The broker appears to have been taken by surprise by Westpac’s soft third quarter performance but was pleased with its CET1 ratio of 10.4% and credit quality. Goldman believes that this should mean its current dividend is sustainable, which supports its buy thesis. I would agree with Goldman on Westpac and think this recent share price weakness is a buying opportunity. Especially for income investors now that its shares provide a trailing fully franked 6.8% yield.

Looking for more buy rated shares? Then don't miss out on these top shares that have been tipped to shine.

The Disruptors: 3 Revolutionary Aussie Companies to Back for 2018

We’re living in one of the most exciting times in investing history. Innovation and a booming culture of entrepreneurship are constantly creating new companies with the potential to make forward-thinking investors very rich. Now more than ever, one small, smart investment could make a huge difference to your wealth.

That’s why at The Motley Fool we’ve been scrutinizing the ASX to uncover the kinds of companies that we believe could turn into the next Atlassian.

We’ve found three exciting companies that we believe re poised to perform in the new year. Click here to uncover these ideas!

Motley Fool contributor James Mickleboro owns shares of Westpac Banking. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The 5 mining stocks we’re recommending in 2019…

For decades, Australian mining companies have minted money for individual investors like you and me. But if you believe the pundits and talking heads on TV, those days are long gone. Finito! Behind us forever…

We say nothing could be further from the truth. To earn the really massive returns, you’ve got to fish where others aren’t fishing—and the mining sector could be primed for a resurgence. That’s why top Motley Fool analysts just revealed their exciting new research on 5 ASX miners they believe could help you profit in 2019 and beyond…

Including:

The best way we see to play the global zinc shortage… Our #1 favourite large-cap miner (hint: it’s not BHP)… one early-stage gold miner we think could hit the motherlode… Plus two more surprising companies you probably haven’t heard of yet!

For free access to our brand-new research, simply click here or the link below. But be warned, this research is available free for a limited time only, and we reserve the right to withdraw it at any time.

Click here for your FREE report!